Protalix BioTherapeutics, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for PLX, updated each market day.
PLX AI Sentiment
AI sees no strong directional signal for Protalix BioTherapeutics, Inc. Common Stock stock over the next 10 market days.
Prediction date: April 30, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Protalix BioTherapeutics, Inc. Common Stock
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
Sector
Exchange
Market Cap
$172,423,313
Cap Tier
Employees
226
Headquarters
HACKENSACK, NJ
Listed Since
Jan. 2, 1996
Website
PLX Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
PLX Volatility
Protalix BioTherapeutics, Inc. Common Stock has shown moderate price volatility over the last 5 trading days. Moderate volatility indicates normal market activity with typical price fluctuations.
